The Wall Street Journal reported on March 5, 2025, that Merck has asked the U.S. patent office to reconsider patents that could prevent it from selling a new version of its cancer drug, Keytruda.
This patent battle specifically concerns the subcutaneous formulation of Keytruda, which is a critical component of Merck's strategy to mitigate the impact of the intravenous version's patent expiration. The outcome of this dispute could significantly affect the commercialization timeline and market exclusivity of the new formulation.
The challenge highlights the ongoing legal complexities in the pharmaceutical industry, particularly for high-value blockbuster drugs. Merck's ability to successfully navigate this patent litigation is crucial for its long-term revenue stability and competitive positioning.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.